Abstract. Data relating opioid treatment and modification of cancer cell migration (a prerequisite of metastasis) both in vitro and in vivo are diverging. In the present report we show that opioids increase the migratory activity of bladder cancer cells (T24 and EJ) and we provide a new mechanistic insight, explaining (at least partially) their action: we report that the enhanced opioid-related cell migration is controlled (in the absence of opioid receptors) through their interaction with bradykinin B2 receptors. Indeed, in these cell lines, opioids increase migration, adhesion, spreading and invasion by re-arranging actin cytoskeleton, increasing MMP-2 and -9 secretion and triggering specific intracellular signaling cascades in a non-opioid receptor mediated manner. An interaction, albeit with low affinity, of opioids with the bradykinin B2 receptor is reported, resulting in the increase of migration, while B2 antagonists revert this action. A systematic assay of different human epithelial cancer cell lines confirmed that only the B2-positive/opioid receptor-negative bladder cancer cells present this opioid-related increased migration/invasive phenotype. We suggest that opioid administration in cancer patients should be re-evaluated, keeping in mind that they may have other beneficial (protection) or adverse effects (spreading of cancer cells), in spite of their unique role in pain relief.

Introduction

A number of studies report that opioids (secreted endogenously or exogenously administered) are implicated in tumor growth, progression and metastasis (1,2). Extensive work has been performed in the field of cancer cell proliferation and apoptosis; however, scarce, heterogeneous, or conflicting data occur, on opioid effect in cell motility and metastasis. Morphine was found to decrease tumor metastasis (3,4), either through a direct action on colon cancer tumor cells (5,6), or by attenuating stress (3,4). Other opioids were found to increase cell motility and invasion of breast and small cell lung carcinoma (7,8), or to have no effect (pancreatic, colon, and head and neck carcinoma) (9). Conversely, very few indirect data concern opioid effects in the genitourinary system: Patel et al reported that opiate addiction results in progression of urogenital injury (10), while opioid agonists were shown to decrease cell proliferation of opossum kidney (OK) cells (11).

The majority of deaths in bladder cancer are due to tumor ability to invade the bladder wall and demonstrate a high propensity for lymphatic and distant metastases. In the present study we have investigated the direct action of opioids (with different receptor selectivity), on the metastatic potential (migratory activity, adhesion, spreading and invasion) of T24 and EJ bladder cancer cells. Our results indicate that opioids can increase the migration of bladder cancer cells, by triggering specific signaling cascades. Their action is not mediated by opioid receptors, but involves bradykinin B2 receptor activation, providing new insights into the role of opioids in malignancies.

Materials and methods

Reagents. Ethylketocyclazosine (EKC) was from Bayer (Leverkusen, Germany). αs1-casomorphine (αs1, Tyr-Val-Pro-Phe-Pro) was synthesized by peptide chemistry methods (12). Diprenorphine was from Reckit&Coleman Co, while morphine and naloxone were from Francopia (Paris, France). HOE 140 (bradykinin B2 receptor antagonist) and sodium orthovanadate (protein tyrosine phosphatase inhibitor) were from Sigma-Hellas (Athens, Greece). SB203580 (p38 kinase inhibitor), PD98058 (ERK1/2 inhibitor), wortmannin (PI3K inhibitor) and SP600125 (JNK inhibitor) were from Calbiochem (San Diego, CA). NG-nitro-L-arginine methyl ester hydrochloride (L-NAME, NOS inhibitor) and (S)-nitroso-N-acetylpenicillamine (SNAP, NO-donor) were from Tocris (Bristol, UK). [3H]U69,593 (41.7 Ci/mmol), [3H]DAMGO (56.8 Ci/mmol), [3H]DPDPE (25.2 Ci/mmol) and [3H]Bradykinin, [2,3-Prolyl-3,4-[3H](N]}
(80 Ci/mmol) were from Perkin Elmer (Waltham, MA). Bradykinin, DAMGO, DPDPE and U69,593, as well as all other chemicals, were from Sigma-Hellas.

**Cell lines and culture conditions.** T24 (bladder), MCF7 (breast), HepG2 (liver), HeLa (cervix) and SKOV-3 (ovary) human carcinoma cell lines were from the ATCC (Teddington, UK); EJ (bladder) cells was a gift from Dr A. Eliopoulos (University of Crete). T24, HeLa and SKOV-3 cells were grown in DMEM, MCF7 cells in DMEM/F12 and EJ and HepG2 cells in RPMI-1640 medium, supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin (5,000 IU/ml)/streptomycin (5,000 µg/ml), in a humidified atmosphere of 5% CO₂, at 37°C. Cell growth was measured by the MTT assay (13).

**Migration assays.** A linear scratch (200-500 µm) was made with a sterile pipette tip at confluence-grown cells, in the absence or the presence of opioids or bradykinin (10⁻⁷ M) with or without a 10 times molar excess of specific opioid (Diprenorphine or Naloxone) or bradykinin antagonist (HOE 140, 10⁻⁷-10⁻⁵ M), kinase- (SB203580 25 µM, PD98059 25 µM, Wortmannin 0.1 µM, or SP600125 10 µM), or protein tyrosine phosphatase (sodium orthovanadate, 10⁻⁶ M) inhibitors. The subsequent colonization of the denuded area was quantified with an inverted microscope (DMIRE2, Leica), at different time-intervals.

Cell trans-migration was also evaluated using the Corning Transwell assay (Cambridge, UK). Cells (2-5x10⁴/100 µl) were seeded in the upper side of an 8 µm pore size polycarbonate membrane, with 300 µl medium at the lower chamber and incubated for 24 h at 37°C. Afterwards, cells were removed from the top surface, while underside (migrated) cells were stained with 0.2% crystal violet for 10 min, solubilized in 30% acetic acid and absorbance was measured at 600 nm.

**Cell adhesion assay.** Treated cells were washed, incubated in serum-free medium for 30 min, resuspended in serum-free medium, seeded on 96-well plates coated with 10 µg/ml collagen type I (100 µl/well), pre-incubated for 90 min at 37°C, at a density of 2x10⁴ for T24 and 3x10⁴ cells per well for the other cell lines and allowed to adhere for different time intervals (15-120 min) at 37°C. Adherent cells were stained with 0.1% crystal violet in 20% methanol for 10 min and lysed with 1% SDS. The absorbance (600 nm) was proportional to the number of cells (14).

**Cell spreading.** Cells were seeded on 6-well collagen I-coated plates. After 2 h (37°C), adherent cells were fixed with 3.7% formaldehyde for 10 min and spreading was quantified with an inverted microscope. Photographs were analyzed using the Image J program (NIH, Bethesda, MD, USA). In all cases, data were normalized per number of cells in each experiment.

**Opioid and bradykinin receptor assays**

**Binding assays.** Binding was performed in whole cells (10⁶ cells/well), in a total volume of 0.4 ml serum-free medium, containing radioactive opioid or bradykinin (~2.5 nM) and 2 mM bacitracin, without (total binding) or with (non-specific binding) a thousand-fold molar excess of the same unlabelled agent (2 h at room temperature for opioids and 3 h, 4°C for BK). Unbound radioactivity was eliminated by washing with cold PBS. Cells were removed from plates with 0.5 ml 2N NaOH, and mixed with 3 ml scintillation cocktail and radioactivity counted, with a 60% efficiency for Tritium. The following conditions were used for the detection of each opioid site: δ opioid sites were detected with [H]DPDPE; Mu sites with [H]DAMGO, while κ sites were identified with [H]U69,593 (11).

**RT-PCR.** Total cellular RNA was isolated with TRIzol (Invitrogen) and treated with DNase I. cDNA was synthesized with reverse transcriptase (SuperScript II RT, Invitrogen). RNA (1 µg) was added to a mixture that contained 5 µM oligo d(T)12-18 primers, 0.5 mM dNTPs, 1X RT buffer, 5 mM dithiothreitol (DTT), 2.5 units RNase OUT, and 10 units SuperScript II RT in a total volume of 20 µl (42°C, 60 min). The PCR reaction mix included 1 µl cDNA, 1 unit Dynazyme II (Finnzymes, Espoo, Finland), and 200 µM dNTP mix, 2 mM MgCl₂, and 500 nM gene-specific primers in a final volume of 25 µl. The conditions for PCR (Primus 96° Advanced Gradient, PeqLab-Biotechnologie, Erlangen, Germany) were denaturation at 94°C for 5 min, followed by 35 cycles of 0.5 min at 94°C; annealing, 0.5 min at 57.5°C and extension, 1 min at 72°C. The primers used were: κ-Opioid Receptor (sense: 5’-CGT ACCAAGGGCTTGCG-3’ and antisense: 5’-TATGTGGAAT

**Confocal laser scanning microscopy for actin cytoskeleton detection.** Cells growing on poly-L-lysine coated coverslips, were fixed (4% paraformaldehyde, 10 min), permeabilized (0.5% Triton X-100, 10 min), stained with rhodamine-labeled phalloidin (45 min), mounted with mounting medium (IMMCO Diagnostics, Buffalo, NY) and visualized with a confocal laser-scanning module (Leica Lasertechtechnik, Heidelberg, Germany) attached to a microscope (Zeiss IM35, Zeiss, Oberkochen, Germany). Cortical filamentous actin (F-actin) to total F-actin ratio was calculated with the aid of Image J program, on an average of 15 cells per condition.

**MMP-2 and -9 secretion by gelatin zymography.** Aliquots of culture conditioned media were electrophoresed in 0.5 mg/ml gelatin type A/10%, SDS polyacrylamide gels, under denaturing/non-reducing conditions (80V). Gels were washed with 2.5% Triton X-100 solution (1 h), incubated at 37°C overnight in a gelatinase activation buffer (0.1 M Tris-HCl, pH 7.4, 5 mM CaCl₂, 200 mM NaCl, 0.02% Brij 35) and stained with 0.5% Coomassie Brilliant Blue in 40% methanol/10% acetic acid. After intensive de-staining, proteolyzed areas appeared as clear bands against a blue background (15). Photographs were analyzed using the Image J program (NIH, Bethesda, MD, USA). In all cases, data were normalized per number of cells in each experiment.

**RT-PCR.** Total cellular RNA was isolated with TRIzol (Invitrogen) and treated with DNase I. cDNA was synthesized with reverse transcriptase (SuperScript II RT, Invitrogen). RNA (1 µg) was added to a mixture that contained 5 µM oligo d(T)12-18 primers, 0.5 mM dNTPs, 1X RT buffer, 5 mM dithiothreitol (DTT), 2.5 units RNase OUT, and 10 units SuperScript II RT in a total volume of 20 µl (42°C, 60 min). The PCR reaction mix included 1 µl cDNA, 1 unit Dynazyme II (Finnzymes, Espoo, Finland), and 200 µM dNTP mix, 2 mM MgCl₂, and 500 nM gene-specific primers in a final volume of 25 µl. The conditions for PCR (Primus 96° Advanced Gradient, PeqLab-Biotechnologie, Erlangen, Germany) were denaturation at 94°C for 5 min, followed by 35 cycles of 0.5 min at 94°C; annealing, 0.5 min at 57.5°C and extension, 1 min at 72°C. The primers used were: κ-Opioid Receptor (sense: 5’-CGT ACCAAGGGCTTGCG-3’ and antisense: 5’-TATGTGGAAT
GGG AGT CCA GC-3', product 120 bp); δ-Opioid Receptor (sense: 5'-ACC AAG ATC TGC GTG TTC CT-3' and antisense: 5'-CGA TGA CGA AGA TGT GGA TG-3', product 210 bp); µ-Opioid Receptor (sense: 5'-CAT GCC ATT CCG ACC TTC-3' and antisense: 5'-AGG CAC TTT CCT AGA GAA TTA GAG C-3', product 100 bp); G3PDH (sense: 5'-TCC ACC ACC CTG TTG CTG TA-3' and antisense 5'-ACC ACA GTC CAT GCC ATC AC-3', product 449 bp). All primers were synthesized by MWG Biotech, Ebersberg, Germany. The products were run on 2% agarose gels and stained with ethidium bromide.

Assay of cell signaling proteins. Detection of signaling molecules was performed using a high-throughput Beadlyte Cell Signaling kit (Upstate, NY) and an xMAP Luminex 100 platform (Austin, TX). Cells were incubated with opioids for different time intervals, washed with ice-cold TBS and lysed using Universal lysis buffer or lysis buffer A, containing phosphatase inhibitors from the manufacturer and completed with complete protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) and sodium orthovanadate (Sigma-Hellas), according to the manufacturer's instructions. The following phosphorylated and total proteins were detected: total and phospho-(Ser473) Akt kinase, total and phospho-(Thr185/Tyr187) ERK/MAP kinase 1/2, total and phospho-(Thr180/Tyr182) p38 kinase, and total and phospho-(Thr183/Tyr185) JNK kinase. Briefly, 25 µl of each sample containing 25 µg of protein were incubated overnight at 4°C in a 96-well plate with microsphere-coupled primary anti-bodies, washed and incubated with signaling molecules-specific reporter antibodies, followed by streptavidin-phycoerythrin according to the manufacturer's protocol and read using the
Luminex 100. Total protein concentration was determined by the Bradford method using the Bio-Rad protein assay kit (Hercules, CA).

For Western blot analysis cells were cultured in six-well plates until 80% confluency. They were treated with morphine ($10^{-6}$ M) for different time periods. Cells were washed three times with ice-cold PBS and lysed in 62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS and freshly added phenylmethylsulfonyl fluoride (10 mM) dithiothreitol, and 50 mM Na$_2$F. Cell lysates or the immunoprecipitates were suspended in Laemmli’s sample buffer and separated by SDS-PAGE. Proteins were transferred onto nitrocellulose membrane, and the membrane was blocked with 5% non-fat dry milk in TBS-T (20 mM Tris, pH 7.6; 137 mM NaCl; 0.05% Tween-20) for 2 h at room temperature. Antibody solutions (in TBS-T containing 3-5% non-fat dry milk) were added overnight at 4°C (first antibody) and for 1 h (second horseradish peroxidase-coupled anti-rabbit antibody, dilution 1:4000). Blots were developed using the enhanced chemiluminescence system, and he band intensities were quantitated by PC-based image analysis (Image Analysis, Inc., Ontario, Canada). The following antibodies were used for the detection of phosphorylation of signaling proteins: ERK1/2, Biosource International, CA (Phospho ERK1/2, pTpY185/187, dilution 1:500, and total ERK1/2 dilution 1:500) and p38MAPK from Santa Cruz Biotechnology, CA (Phospho p38MAPK, c-20, sc535 dilution 1:300 and total p38MAPK dilution 1:300).

B2 receptor silencing. Cells were treated with siRNA for B2 receptor (bradykinin B2R siRNA, Santa Cruz Biotechnology, CA, sc-29822) according to the manufacturer instructions. Briefly, cells were incubated with siRNA for 24 h, siRNA containing medium was removed and B2 receptor expression was assayed by real-time PCR for bradykinin B2 receptor after
24, 48 and 72 h. A complete silence of expression was achieved after 72 h. Afterwards, a scratch migration assay was performed in the absence or in the presence of morphine. A scrambled siRNA was used as a negative control.

**Statistical analysis.** Data are expressed as the means ± SEM from the indicated number of experiments. All results are presented as a percentage compared to untreated cells (control=100%). SEM for control was calculated by extrapolation the SEM of raw data. Significance of difference between untreated and treated cells with various reagents was determined by parametric methods, with the aid of the Origin V 5.0 (Microcal Software, Northampton, UK) and the Systat V 10.0 (SPSS, Chicago, IL) microcomputer programs. For couple comparisons, we have used Student's t-test. Statistical significance was set to p<0.05.

**Results**

**Opioids accelerate migration, adhesion and spreading of bladder cancer cells.** When bladder cancer cells were incubated with a maximal concentration of different opioid agonists (EKC, αS1, morphine, 10^-6 M), a significant increase of migration, adhesion and spreading was observed. Morphine, EKC and αS1 induced time-related wound coverage of T24 cells (Fig. 1A and B) while they accelerated cell transmigration by 16-43%, after 24 h (Fig. 1C). However, this effect was substance-related, as DPDPE, DAMGO and U69,593 (δ-, µ- and κ-opioid agonists respectively) exhibited a non-significant effect on migration (26%, 5% and 20% respectively) (Fig. 1D). Similar results were obtained with EJ cells (not shown).

Morphine, EKC and αS1 increased also T24 cell adhesion, in a dose-dependent manner, with EC50s of 1.26x10^-11, 2.56x10^-12 and 1.46x10^-11 M, respectively (Fig. 2A). A similar, but less profound induction was also found in EJ cells, with EC50s of 3.9x10^-9, 1.61x10^-11 and 1.18x10^-11 M for morphine, EKC and αS1 respectively (Fig. 2B).

Cell spreading was also affected by opioids (2 h, 10^-6 M): Morphine accelerated T24 cell spreading, increasing the average cell area by ~29% (Fig. 2C and D), while EKC and αS1 induced a significant but less profound effect. Cell shape was also modified by opioids: while untreated cells were round, most treated cells were spindle-like shaped (Fig. 2C). A similar effect was also found in EJ cells (Fig. 2E-F).
Opioids increase the invasive ability of T24 cells by increasing the secretion of matrix metalloproteinases. Opioids (10^{-6} M) were found to increase the invasiveness of T24 and EJ cells by 20-40% and 15-20%, respectively (Fig. 3A), in a dose-dependent manner (not shown). ECM disruption and invasion largely depends on the secretion of matrix metalloproteinases (MMP). MMPs comprise a large family of matrix degrading enzymes (16), with MMP-2 and MMP-9 being the most active isoforms (17-19). Indeed, pro-MMP-2 (72 kDa) and pro-MMP-9 (92 kDa) secretion in the culture medium paralleled the invasiveness of T24 and EJ cells (Fig. 3B and C). Additionally, opioids induced the secretion of active MMP-9 (82 kDa) by T24 cells (Fig. 3B). In EJ cells, in which opioid-induced invasiveness was lower, active MMP-9 was not found. However, in contrast to other cell systems, in which opioid-related MMP secretion is under NOS control (20), in bladder carcinoma cells, neither the NOS inhibitor L-NAME (0.5 mM) nor the NO donor SNAP (0.05 mM) influenced their secretion, suggesting a NOS-independent pathway of opioid-related MMP secretion (not shown).

Opioids regulate actin cytoskeleton rearrangements. Adhesion and spreading are usually linked to rearrangements of actin cytoskeleton; in T24 cells, opioid (10^{-6} M) effects on actin cytoskeleton are time-related (morphine effect is shown in Fig. 4A, while the effect of EKC and α_{5} at 15 min is presented in Fig. 4B). Opioid-treated cells displayed rapid (2-10 min) accumulation of cortical actin, formation of filamentous actin-containing complexes, accumulated most prominently within filopodia (Fig. 4A), extending from marginal edges of the cell and numerous microspikes. The ratio of cortical to total F-actin was 0.55±0.02 in untreated cells, while morphine-, EKC- and α_{5}-treated cells expressed a significantly increased ratio (0.66±0.02, 0.65±0.03 and 0.59±0.03; p<0.001). EJ cells (not presented) revealed similar changes. During

Figure 4. Effect of opioids on actin cytoskeleton. Confocal laser scanning micrographs of T24 cells stained with rhodamine-phalloidin. (A) Actin rearrangement after treatment with morphine (10^{-6} M) at different time-intervals (0, 2, 5, 10 and 15 min). (B) Actin cytoskeleton after treatment with 10^{-6} M morphine, EKC and α_{5}, for 15 min. (large arrows) lamellipodia, (arrows) filopodia and (arrow heads) cortical actin. (C) Actin cytoskeleton after treatment with 10^{-6} M morphine, 10^{-5} M HOE 140 and their combination, for 15 min. (D) Formation of lamellipodia (arrows) during wound healing repair in the presence of 10^{-6} M morphine for different time intervals (0, 1, 2 and 3 h).
migration and wound healing, morphine induced the marked formation of stress fibers and lamellipodia to the direction of movement (Fig. 4D). Lamellipodia formed in the presence of morphine and subcortical actin distribution were more intense, compared to untreated cells (cortical/total F-actin = 0.62±0.01 for morphine-treated cells compared to 0.51±0.01 for untreated cells, p<0.001).

**Signaling pathways involved in migration induced by opioids.** Morphine induced a rapid and transient p38 kinase phosphorylation (2.5-fold increase after 5 min and a return to basal levels after 10 more minutes) and a delayed (15 min) phosphorylation of ERK 1/2 (3.5-fold) and JNK (0.4-fold). No effect on the phosphorylation of Akt was observed (not shown), suggesting that this key signaling molecule might not be a downstream effector for the induction of migration and adhesion of bladder cancer cells (Fig. 5A). The results on the signaling molecules, identified by a multiplex-based assay, were verified with Western blotting, as presented in Fig. 5B.

**Table I. Opioid and bradykinin B2 receptor expression in the different cancer cell lines tested in the present study.**

<table>
<thead>
<tr>
<th>Opioid receptors Binding (sites per cell)/PCR</th>
<th>Bradykinin B2 receptor Binding (sites per cell)/PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>µ</td>
<td>κ</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>T24</td>
<td>-/-</td>
</tr>
<tr>
<td>EJ</td>
<td>-/-</td>
</tr>
<tr>
<td>MCF7</td>
<td>1158/+</td>
</tr>
<tr>
<td>HepG2</td>
<td>-/-</td>
</tr>
<tr>
<td>HeLa</td>
<td>-/-</td>
</tr>
<tr>
<td>SKOV-3</td>
<td>-/-</td>
</tr>
</tbody>
</table>

Opioid sites were assayed by ligand binding assays and RT-PCR as detailed in Materials and methods.

Figure 5. Signaling molecules implicated in the opioid effect (A) Phospho/total ratio of ERK 1/2 kinase, p38 kinase and JNK kinase after incubation of T24 cells with 10^{-6} M morphine, for 5 and 15 min. Results are presented as Median Fluorescence Intensity, (MFI, assayed by a multiplex bead assay, using specific antibodies), normalized to non-treated cells (control=1) and performed in duplicates, as described in Materials and methods. (B) Phospho/total ratio of ERK 1/2 kinase and p38MAPkinase after incubation of T24 cells with 10^{-6} M morphine, for 5 and 15 min and assayed by Western blotting. Band intensity results are presented normalized to non-treated cells (control=1). Results are the means of at least three independent experiments and ´ denotes statistically significant results (p<0.05). (C) Inhibition of the action of morphine on cell migration, in the presence of wortmannin (10^{-7} M), SB203580 (25 µM), PD98059 (25 µM), SP600125 (10 µM) and sodium orthovanadate (10^{-6} M).
The involvement of the above signaling molecules was further confirmed by the use of the general protein tyrosine phosphatase inhibitor sodium orthovanadate ($10^{-6}$ M). As shown, inhibition of the action of phosphatases reverts the effect of opioids on migration.

The enhanced effect of opioids on T24 and EJ cell migration involves bradykinin receptors. The results presented above indicate that opioids increase migration, invasion and spreading of bladder cancer cells, rearranging the actin cytoskeleton and inducing the phosphorylation of key signaling molecules. However, ligand binding assays (assaying the active receptor protein) and RT-PCR, assaying the mRNA transcript (Table I, Fig. 1E) revealed that bladder cancer cells do not express opioid receptors, while opioid antagonists (naloxone and diprenorphine) failed to inhibit the action of morphine (not shown). Therefore, the effect of opioids on bladder cancer cell migration is independent of the presence of opioid receptors and should be mediated through their interaction with other membrane-related molecules.

A number of membrane receptors, are involved in the migratory activity and enhanced invasion of cancer cells, inducing signaling molecule changes as those presented here: hepatocyte growth factor receptor (c-met) (21), CXCR4 chemokine receptor (22), bradykinin (BK) B2 receptor (23,24), urokinase plasminogen activator receptor (uPAR) (25) and vascular endothelial growth factor receptor (VEGF) (26,27). In order to point out the most probable candidate we examined the effect of opioids on migration of a number of cell lines, reported to express these receptors: MCF7 breast cancer, HepG2 hepatocellular carcinoma, HeLa cervix carcinoma, that express c-met, uPAR (28-35) and VEGF receptors (36,37), and CXCR4 (38-40) and SKOV-3 ovarian carcinoma cells, expressing only c-met and uPAR (27). MCF7 was the only cell line expressing functional opioid receptors (Table I). Morphine inhibited hepatocellular (HepG2) and cervical carcinoma cell (HeLa) migration (14% and 15% respectively), did not affect breast (MCF7) and ovarian carcinoma cells (SKOV-3), while it decreased the adhesion of HeLa cells by 16%. Additionally, no significant effect was observed on the spreading of MCF7, HepG2 and SKOV-3 cells indicating that the enhancement of the migratory activity by opioids is characteristic of the bladder cancer cells (Table II; other opioids had a similar action on the assayed parameters, not presented). As these cell lines (with the
Table II. Migration (wound healing), transmigration, adhesion and spreading of cancer cells of different origin (bladder-T24 and EJ, breast-MCF7, liver-HepG2, ovary-SKOV-3 and cervix-HeLa) in the presence of morphine (10^{-6} M).

<table>
<thead>
<tr>
<th></th>
<th>Migration (wound healing)^a</th>
<th>Transmigration^b</th>
<th>Adhesion^c</th>
<th>Spreading^c</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Morphine</td>
<td>Control</td>
<td>Morphine</td>
</tr>
<tr>
<td>T24</td>
<td>35.3±6.2</td>
<td>52.9±4.5</td>
<td>100±3.9</td>
<td>127±2.9</td>
</tr>
<tr>
<td>EJ</td>
<td>19.8±1.7</td>
<td>28.1±6.2</td>
<td>100±2.2</td>
<td>118±3.2</td>
</tr>
<tr>
<td>MCF7</td>
<td>30.7±13</td>
<td>36.7±10</td>
<td>100±5.2</td>
<td>111±5.5</td>
</tr>
<tr>
<td>HepG2</td>
<td>28.3±2.5</td>
<td>17.8±2.5</td>
<td>100±3.2</td>
<td>83.3±4.1</td>
</tr>
<tr>
<td>SKOV-3</td>
<td>13.1±4.5</td>
<td>16.2±4.4</td>
<td>100±3.6</td>
<td>95±4.5</td>
</tr>
<tr>
<td>HeLa</td>
<td>28.2±2.2</td>
<td>17.5±1.2</td>
<td>100±4.2</td>
<td>86±3.4</td>
</tr>
</tbody>
</table>

^a T24, EJ and SKOV-3 cells were examined after 12 h, MCF7 and HeLa cells after 24 h and HepG2 cells after 3 days. Results are presented as % wound closure of the total wound area at 0 h. ^b Transmigration experiments were assayed after 24 h for all cells. ^c Adhesion and spreading were assayed after 2 h for all cells. ^d Results are normalized to control (=100%)±SEM of at least three independent experiments performed in triplicate; ^e denotes statistically significant differences compared to control, as evaluated with t-test.

exception of MCF7 cells) do not bear functional opioid receptors (Table I), and the effect of opioids was different from that found in bladder cells, we have ruled out the implication of c-met, uPAR, VEGF and CXCR4 receptors on migration, adhesion, invasion and spreading of T24 and EJ cells. It derives that a potential candidate explaining our data is the BK B2 receptor. BK B2 receptor is expressed by T24 and MCF7 cells (23) and it has been previously found to interact with opioids (41,42) as well as to induce bladder cancer motility (24).

T24 and EJ cells bear functional BK B2 receptors (1226 and 700 sites/cell respectively) with a K_D of 0.7 nM (Fig. 6C). Morphine was a weak competitor of bradykinin binding, interacting with an almost 1000-times lower affinity. Additionally, incubation of T24 cells with morphine (10^{-6} M) and the specific bradykinin B2 receptor antagonist HOE 140 (10^{-7}-10^{-5} M) inhibited migration in a dose-dependent manner (Fig. 6A). Moreover, changes on actin cytoskeleton induced by morphine in T24 cells were partly reversed by HOE 140 (10^{-5} M) (Fig. 4C). Similarly, the effect of morphine on the ratio of cortical/total F-actin was affected in the presence of HOE 140 (0.51±0.03, 0.62±0.02, 0.44±0.03 and 0.55±0.03 for control, morphine, HOE 140 and morphine+HOE 140, respectively).

The specificity of B2 receptor involvement in cell migration was confirmed by incubating the different cell lines with opioids (morphine, 10^{-6} M), in the presence of the BK B2 antagonist HOE 140 (10^{-5} M). As presented in Fig. 6D, in EJ cells, the migratory effect of morphine was reverted by the addition of HOE 140, suggesting the implication of BK B2 receptors. In contrast, the effect of morphine was not modified in the other cell lines, with the exception of HepG2. However, taking into consideration the absence of BK B2 and opioid receptors (Table I) this could be due to an interaction of opioids and BK antagonists with another unidentified membrane receptor system.

Finally, the effect of morphine was also studied in T24 cells that were transiently transfected with specific siRNA for B2 receptor. Seventy-two hours after transfection B2 receptor expression was completely silenced, as assayed by real-time PCR (data not shown). When these cells were used for the migration assay, morphine-induced T24 cell migration (Fig. 6B) was inhibited, indicating a B2 receptor mediated effect.

Discussion

Bladder cancer is the fourth most common cancer and the ninth leading cause of cancer death (43,44). Most of the cases are transitional cell carcinoma (TCC) and 20-30% of them express the lethal non-papillary invasive TCC phenotype, with lymphatic and distant metastasis. The bladder concentrates the excreted amounts of administered opioids and their metabolites, while endogenous opioid peptides are produced within the urogenital tract (45,46). Furthermore, ~45% of bladder tumor-infiltrating lymphocytes consist of T-cells (47), able to secrete endogenous opioids (48-50), that can affect tumor progression. However, the effect of opioids on cell migration, adhesion, spreading and invasion in solid organs is much less studied than their action on cell proliferation and apoptosis. In fact, conflicting results have been reported, with opioids decreasing (5,6,51), increasing (7,8,52), or having no effect on cell motility (9). Our data extend and confirm these observations: depending on the cell line, opioids were found to exert no effect (MCF7 and SKOV-3 cells), decrease (HepG2 and HeLa cells) or increase (T24 and EJ), migration, adhesion, spreading and invasion.

Cell spreading, migration and invasion of solid organs includes disruption of the extracellular matrix, under the action of proteases, especially MMPs (53-55), which are also been involved in early steps of tumor evolution, proliferation and angiogenesis (56). The results of the present, as well as previous study (20), indicate that opioids might efficiently modify MMP secretion, depending on the cell type and the mechanism involved. Indeed, previous data indicate that opioids decrease MMP secretion by mouse fibrosarcoma cells, through the NO/NOS system (20), while our findings indicate that in human bladder cancer cells, they increase MMP secretion in a NO/NOS-independent mechanism.

Our results further suggest that opioids promote motility and invasiveness of bladder cancer cells, in a non-opioid receptor-mediated manner, through rapid modification of
signaling molecules (p38 MAPK, JNK and ERK 1/2 kinases) and actin cytoskeleton redistribution. Reported data indicate an interplay of opioids with an increasing number of alternative membrane receptor systems in addition to opioid receptors: such as somatostatin (reviewed in ref. 57), adrenergic (58), chemokine (59,60), or bradykinin receptors (41,42). Furthermore, there are scarce data indicating an internalization of opioid peptides, which can interact subsequently with signaling pathways (61). Our data provide a mechanistic framework for the interaction of opioids with bradykinin B2 receptors in bladder cancer cells: i) B2 receptors are expressed in T24 cells and to a lesser extent in EJ cells, ii) B2 receptor activation is able to induce the observed changes in signaling molecules (62; reviewed in ref. 63), iii) co-incubation of bladder cancer cells with the specific B2 receptor antagonist HOE 140, or silencing it with siRNA, reverses the action of opioids in T24 and EJ cells, iv) opioids have an inhibitory or no effect on cancer cells of different origin that do not express the B2 receptor or the opioid receptors and v) in this latter case (MCF7 cells), their action is mediated via opioid receptors, since co-incubation of the cells with HOE 140 does not revert opioid action. Furthermore, bradykinin has been previously found to induce the migratory activity of bladder cancer cells (24), a result which is partially mimicked by opioids. Similar interaction of opioids, with bradykinin receptors has been recently reported. More specifically, dynorphin A was found to activate bradykinin receptors and maintain neuropahtic pain (41,42). The affinity of dynorphin A for the bradykinin B2 receptor (1.4-2 µM) is comparable to the affinity we have found for morphine (1.7 µM). However, the physiological significance of this finding needs further study, as all opioids interact on B2 receptor with a 1000-fold lower affinity than the cognitive ligand. An alternative possibility, as all opioids interact on B2 receptor with a 1000-fold lower affinity than the cognitive ligand, suggests a pluripotency of opioid-other membrane receptor interaction of opioids with bradykinin B2 receptors and maintain neuropathic pain (41,42). The affinity of dynorphin A for the bradykinin B2 receptor (1.4-2 µM) is comparable to the affinity we have found for morphine (1.7 µM). However, the physiological significance of this finding needs further study, as all opioids interact on B2 receptor with a 1000-fold lower affinity than the cognitive ligand. An alternative possibility, as all opioids interact on B2 receptor with a 1000-fold lower affinity than the cognitive ligand, suggests a pluripotency of opioid-other membrane receptor interactions, in the absence of cognitive receptors. In view of these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that they these findings, using opioids in cancer patients, in spite of their unique role in pain relief, one should keep in mind that